A Real‐World Study Characterizing a US Population of Patients Receiving Rituximab With Gemcitabine and Oxaliplatin for Relapsed or Refractory Large B‐Cell Lymphoma
This retrospective observational study characterizes R‐GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron Health electronic health record‐derived database comprising patient‐level data primarily from US community oncology practices.
Abstract
Data for the use of rituximab, gemcitabine, and oxaliplatin (R‐GemOx) for relapsed/refractory (R/R) large B‐cell lymphoma (LBCL) in the United States are limited. This retrospective observational study characterizes R‐GemOx treatment patterns and outcomes among patients with R/R LBCL from the nationwide, longitudinal Flatiron Health electronic health record‐derived database comprising patient‐level data primarily from US community oncology practices.
We compared outcomes and toxicities of weekly paclitaxel plus carboplatin‐based (wTC) and cisplatin‐based (CDDP) concurrent chemoradiotherapy (CCRT) in FIGO stage IB2–IVA cervical cancer cases.
Ayano Shimizu, K. Chikazawa, Y. Fukuda et al.· The journal of obstetrics an...· 0 citations
Biweekly gemcitabine plus nab‐paclitaxel plus nab‐paclitaxel (GnP) has been evaluated in retrospective studies as an alternative dosing schedule, whereas prospective evidence remains limited.
K. Ikezawa, T. Imai, R. Takada et al.· Cancer Reports· 0 citations
In this real-world study, higher rates of immune-related adverse events were observed than those reported in the KEYNOTE-522 trial, although severe toxicities remained uncommon.
E. Boujeke, Aaron Catalan, L. Arayan et al.· Current Oncology· 0 citations
Although immunotherapy combined with platinum‐based chemotherapy is now the standard first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), the benefit of continuing immune checkpoint inhibitors (ICIs) after disease progression (PD) remains uncertain. This real‐world study assessed the efficacy and...
Yu-Xia Wang, Yun-Feng Tong, Yang Pan et al.· Cancer Medicine· 0 citations
This retrospective observational cohort study assessed biomarker testing and guideline‐concordant matched first‐line therapy use and evaluated their associations with overall survival, diagnosis‐to‐treatment intervals, and 6‐month physical functioning in patients with advanced solid tumors.
Onur Baser, Yi-Jia Sun· Cancer Medicine· 0 citations
In NRG Oncology/RTOG 1010, HER2‐targeted escalation did not improve survival or patient‐reported outcomes in localized esophageal adenocarcinoma. The study illustrates that biologic plausibility and metastatic success do not guarantee benefit in the curative‐intent setting and emphasizes the need for rigorous, patient‐...
T. J. Brown, N. Hornstein, U. Grewal et al.· Cancer· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
